Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.12

€2.12

-3.260%
-0.07
-3.260%
€1.00
 
28.03.24 / Tradegate WKN: A1X3W0 / Name: Medigene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Medigene AG Stock

Heavy losses for Medigene AG today as the stock fell by -€0.070 (-3.260%).
Currently there is a rather negative sentiment for Medigene AG with 1 Buy predictions and 3 Sell predictions..
A target price of 1 € results in a potential of -52.83% which would mean heavy losses compared to the current price of 2.12 € for Medigene AG.
Our community identified positive and negative aspects for Medigene AG stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Medigene AG stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Medigene AG in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Medigene AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Medigene AG -3.260% 6.266% 46.207% 9.278% 33.333% -44.503% -74.626%
Formycon AG -0.960% -0.645% -4.644% -31.250% -17.204% -25.962% 52.224%
MagForce AG 25.000% 25.000% -33.333% -9.091% 150.000% -99.955% -99.961%
Biofrontera AG 0.300% -3.725% 5.660% -71.525% -17.445% -85.732% -94.085%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-14

Upon reviewing the financial statements of Medigene, a biotechnology and medical research firm, it is evident that the company has experienced some fluctuations in its financial position over the last few years. The balance sheets, cash flow statements, and income statements for the years 2020, 2021, and 2022 reveal several interesting insights that could potentially impact the short and long-term prospects of the company.

*Pros: *

Increasing Revenue: The total revenue of Medigene has been on an upward trend from €8,749,000 in 2020 to €10,463,000 in 2021 and further to €31,247,000 in 2022. This growth in revenue signifies that the company's products and services are gaining acceptance in the market, and it has been successful in expanding its customer base.

Comments

systinvest hat das Wertpapier Medigene AG in seinem Wikifolio Aktienwertselektion mit System gekauft.
Show more

Buy Medigene AG
Show more

Buy Medigene AG
Show more

News

Medigene to Present at Upcoming Conferences
Medigene to Present at Upcoming Conferences

Planegg/Martinsried (19.02.2024)

 

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell

Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors
Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors

Planegg/Martinsried (12.02.2024)

 

-          Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program

Medigene AG: Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
Medigene AG: Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference

Planegg/Martinsried 19.12.2023

 

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell